It seems bad news follows good. Just a matter of weeks after announcing a new development deal with generics giant Hikma (HIK), respiratory specialist Vectura (VEC) has revealed one of its own drugs - known as VR475 - has failed in a third-stage clinical trial.
IC TIP:
Buy
at
71p
The drug failed to show any meaningful difference in a study with patients suffering from severe uncontrolled asthma and, based on these results, Vectura won’t pursue further development or partnering of VR475.
